Efficacy and safety of endoscopic papillectomy: a multicenter, retrospective, cohort study on 227 patients

Abstract

Background: Endoscopic papillectomy is a minimally invasive treatment for benign tumors of the ampulla of Vater or early ampullary carcinoma. However, reported recurrence rates are significant and risk factors for recurrence are unclear. Objective: The aims of this study were to evaluate the efficacy and safety of endoscopic papillectomy and to identify risk factors for recurrence and adverse events. Methods: All patients who underwent endoscopic papillectomy at five tertiary referral centers between January 2008 and December 2018 were included. Recurrence was defined as the detection of residue on one of the follow-up endoscopies. Treatment success was defined as the absence of tumor residue on the last follow-up endoscopy. Results: A total of 227 patients were included. The resections were en bloc in 64.8% of cases. The mean lesion size was 20 mm (range: 3–80) with lateral extension in 23.3% of cases. R0 resection was achieved in 45.3% of cases. The recurrence rate was 30.6%, and 60.7% of recurrences were successfully treated with additional endoscopic treatment. Finally, treatment success was achieved in 82.8% of patients with a median follow-up time of 22.3 months. R1 resection, intraductal invasion, and tumor size > 2 cm were associated with local recurrence. Adverse events occurred in 36.6% of patients and included pancreatitis (17.6%), post-procedural hemorrhage (11.0%), perforation (5.2%), and biliary stenosis (2.6%). The mortality rate was 0.9%. Conclusion: Endoscopic papillectomy is an effective and relatively well-tolerated treatment for localized ampullary tumors. In this series, R1 resection, intraductal invasion, and lesion size > 2 cm were associated with local recurrence.

Lockdown period during SARS COVID-19 endemic outbreak in Taiwan did not cause an increase of the complications nor mortality of patients received endoscopic retrograde cholangiopancreatography: A single-center retrospective study

“…The incidence of post-ERCP pancreatitis is ranging from 2% to 16%. [19][20][21] Post-EPT bleeding and perforation varied from 0.02% to 11% and 0.06% to 0.72%, respectively. [21][22][23] Finally, the failure rate of cannulation is reported as ranging from 16% to 24%.…”

“…[19][20][21] Post-EPT bleeding and perforation varied from 0.02% to 11% and 0.06% to 0.72%, respectively. [21][22][23] Finally, the failure rate of cannulation is reported as ranging from 16% to 24%. [24][25][26] The performance indicators, including cannulation and complication rates, were similar between 2019 and 2021 and compatible with the previous studies.…”